• Mission
• Maps and Directions
• Contact Us
• Directory
• Combining Basic Research and Clinical Trials
• Links

• Administration
• Atherosclerosis and Thrombosis
• Bionutrition
• Biostatistics and Informatics
• Core Laboratory
• Diabetes and Metabolism
• Emergency Care
• Genomics
• Hemostasis and Thrombosis
• Neurology
• Nursing
• Oncology
• Pharmacogenomics

GENOMIC UNIT

Director: Stefano Martinotti
Phone: +39 0871 541341
E-Mail: smartinotti@unich.it

The facility will provide a prompt and extensive bio-molecular service devoted to the investigation of genetic polymorphic variants of genes involved in the pathogenesis of human disease. Tools for a software-assisted analysis of imported molecular data will be used for comparative structural studies and expression profile analysis of sequences evaluated through quantitative PCR and microarray assay. We will serve a biomolecular platform where all the molecular mechanisms involved in the pathophysiology of intracellular signalling will be evaluated, analytically investigated and validated through in vitro and in vivo modelling.
Advanced biomolecular techniques mostly including RNA transcript analysis, cell transfection assays, structural and functional characterization of gene promoter activity, cloning and expression of active biomolecular species and generation of transgenic and knock out inbred animals will be widely used.

Clinical Investigator for the following drugs:

2003
- Gliclazide Bioequivalence in Biabetes (SPL’S Italy))
- Citalopram Bioequivalence (SPL Italy)
- Budesonide Bioequivalence (Genetic SpA)
- Beclometasone Bioequivalence (Genetic SpA)
- Cervedilol Bioequivalence 6,25 mg in Hypertension (SPL)
- Carvedilol Bioequivalence 25 mg in Hypertension (SPL)

2004
- Enalapril 20 mg Bioequivalence in Hypertension (Genetic SpA)
- Enalapril 5 mg Bioequivalence in Hypertension (Genetic SpA)
- Lamotrigin 5 mg Bioequivalence in Epilepsy (SPL)
- Lamotrigin 200 mg Bioequivalence in Epilepsy (SPL)
- Gabapentin Bioequivalence in Epilepsy (SPL)

2005
- Bethaistine Bioequivalence as Antihistaminic (Formenti)
- Samital Tollerability in Inflammation (Indena)
- Samital efficacy in Inflammation (Indena)
- Fluconazol Bioequivalence as a antimicotic (Genetic)
- Ciprofloxacin Bioequivalence as an antibiotic (SPL)
- Meloxicam Bioequivalence in Inflammation (RD)

2006
- Fluconazol Bioequivalence as an antimicotic (TS Farmaceutici)
- Tachipirina Bioequivalence in Inflammation (Angelini)
- Ketoprofene Bioequivalence in Inflammation (IBI)
- Cetirizina Bioequivalence as an antihistaminic (R&D)
- Ursodesossicolic acid Bioequivalence in epatology (R&D)
- Atorvastatin Bioequivalence as an anticholesterol (MADER)
- Claritromicin Bioequivalence as an antibiotic (Genetic)
- Omeprazol Fast Bioequivalence in gastric (ERREKAPPA)
- Simvastatina Bioequivalence in dislipidemy (R&D)
- Enalapril 6 mg Bioequivalence in Hypertension (R&D)
- Enalapril 12,5 mg Bioequivalence in Hypertension (R&D)
- Piroxicam Tollerabilità in Inflammation (Boutì)
- Piroxicam efficacy in Inlfammation (Boutì)
- Lorazepan Bioequivalence as an ansiolitic
- Ketoprofen Patch tollerability (Boutì)

2007
- Ketoprofen Patch efficacy (Boutì)
- Fluticason Bioequivalence in Inflammation (Genetic)
- Ibuprofen Bioequivalence in Inflammation (Angelini)